Waters (WAT) News Today

Waters Corporation (NYSE: WAT) is trading lower amid mixed analyst views on its pending acquisition of Becton Dickinson’s Biosciences & Diagnostic Solutions unit. While some firms see long-term upside, others have trimmed ratings and flagged legal and market-price headwinds.

• Positive Sentiment: Stifel views the BD Bioscience deal as a strategic fit that could bolster Waters’ long-term growth prospects. Waters, BD Bioscience deal ‘looks to be a good fit,’ says Stifel
• Positive Sentiment: Robert W. Baird maintains an “outperform” rating on WAT, citing a roughly 21.5% upside despite lowering its price target to $352.00. Waters (NYSE:WAT) Price Target Cut to $352.00 by Analysts at Robert W. Baird
• Neutral Sentiment: The WSJ notes the BD unit deal is a long-term play but carries execution risks around integration and regulatory approvals. Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks
• Neutral Sentiment: A Bank of America Securities analyst keeps a cautious Hold on Becton Dickinson amid uncertainty over projected revenues and the Waters merger’s timeline. Cautious Hold Rating on Becton Dickinson Amid Uncertainties in Waters Merger and Revenue Projections
• Negative Sentiment: Wells Fargo & Company downgraded WAT to Hold, citing near-term valuation concerns as the deal progresses. Waters (NYSE:WAT) Downgraded by Wells Fargo & Company to Hold
• Negative Sentiment: Shares hit a fresh 12-month low, raising questions about entry points for worried investors. Waters (NYSE:WAT) Reaches New 12-Month Low - Should You Sell?
• Negative Sentiment: A law firm led by former Louisiana AG Charles Foti is probing the merger, creating potential litigation risk post-close. WATERS CORPORATION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Waters Corporation - WAT